Total: 6212

Sirolimus-eluting stent with abluminal-only biodegradable polymeric coating in the treatment of native coronary artery lesions: results of the prospective multicenter inspiron real life II and latitude Trials

J. Am. Coll. Cardiol; 84 (18 Suppl. B), 2024
BACKGROUND Inspiron is a third-generation drug-eluting stent with abluminal-only biodegradable polymeric coating designed for fast and homogeneous reendothelialization, possibly improving clinical outcomes. This study aimed to evaluate the safety and clinical performance of the Inspiron sirolimus-eluting...

Restenosis, procedural success and long-term outcomes after percutaneous mitral balloon commissurotomy in rheumatic mitral disease: large single-center experience

J. Am. Coll. Cardiol; 84 (18 Suppl. B), 2024
BACKGROUND Percutaneous mitral balloon commissurotomy (PMBC) remains the fust choice of treatment in appropriate candidates with mitral valve (MV) stenosis (MS) and ideal anatomy. The objective of this study was to identify the risk factors of MV restenosis in a large cohort of patients submitted to PMBC...

Up to 20 years’ follow-up of severe pulmonary artery hypertension percutaneous mitral balloon commissurotomy due to rheumatic mitral valve disease

J. Am. Coll. Cardiol; 84 (18 Suppl. B), 2024
BACKGROUND Percutaneous balloon mitral commissurotomy (PMBC) is an engaging therapy in patients with mitral valve (MV) stenosis and pulmonary hypertension (PH). The objective of this study was to analyze the effect of immediate and long-term outcomes in patients with severe PH due to theumatic mitral val...

Outcomes of guideline-recommended percutaneous coronary intervention in women with obstructive coronary artery disease

J. Am. Coll. Cardiol; 84 (18 Suppl. B), 2024
BACKGROUND Previous studies have shown that women with coto nary artery disease (CAD) are less likely to undergo angiography and have less favorable clinical outcomes after percutaneous coronary intervention (PCI). METHODS This observational longitudinal cohort study with pro spective clinical follow up ...

Clinical impact of sex differences and procedural setting in transcatheter aortic valve implantation

J. Am. Coll. Cardiol; 84 (18 Suppl. B), 2024
BACKGROUND Transcatheter aortic valve implantation (TAVR) is a well-established treatment for symptomatic patients with aortic ste nosis. Yet the impact of sex differences and public vs private proce dural setting on TAVR outcomes remain uncertain. METHODS The RIBAC-NT (Brazilian Registry for Evaluation ...

Visualization of left main ostium by means of optical coherence tomography: a feasibility study

J. Am. Coll. Cardiol; 84 (18 Suppl. B), 2024
BACKGROUND Because of the need for guiding catheter engagement for transient blood clearance during image acquisition, optical coherence tomography (OCT) is not recommended when assessment of the left main (LM) ostium is necessary. METHODS Wetested the ability to visualize the LM ostium with good- qualit...

Predictors of conduction system disturbances resulting in a new permanent pacemaker implantation within the Landmark Trial

J. Am. Coll. Cardiol; 84 (18 Suppl. B), 2024
BACKGROUND The need for permanent pacemaker implantation (PPMI) after transcatheter aortic valve implantation (TAVR) is a serious complication that adds additional risk for the patient. It also lengthens the hospitalization and increases costs. Unknown is the PPMI rate of the new balloon expandable Myval...

Pharmacogenetics of DPYD and treatment-related mortality on fluoropyrimidine chemotherapy for cancer patients: a meta-analysis and trial sequential analysis

BMC cancer; 24 (1), 2024
BACKGROUND: Fluoropyrimidines are chemotherapy drugs utilized to treat a variety of solid tumors. These drugs predominantly rely on the enzyme dihydropyrimidine dehydrogenase (DPD), which is encoded by the DPYD gene, for their metabolism. Genetic mutations affecting this gene can cause DPYD deficiency, d...

Health-related quality of life with rivaroxaban plus aspirin vs. aspirin alone in chronic stable cardiovascular disease: Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial

Eur Heart J Open; 4 (5), 2024
AIMS: This study aimed to compare the effects of the combination of rivaroxaban and aspirin with aspirin alone on health-related quality of life in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial. METHODS and results: Health-related quality of life assessed using t...